| Title |
Functional analysis of the DEPDC1 oncoantigen in malignant glioma and brain tumor initiating cells
|
|---|---|
| Published in |
Journal of Neuro-Oncology, May 2017
|
| DOI | 10.1007/s11060-017-2457-1 |
| Pubmed ID | |
| Authors |
Ryogo Kikuchi, Oltea Sampetrean, Hideyuki Saya, Kazunari Yoshida, Masahiro Toda |
| Abstract |
DEP domain containing 1 (DEPDC1) is a novel oncoantigen expressed in cancer cells, which presents oncogenic activity and high immunogenicity. Although DEPDC1 has been predicted to be a useful antigen for the development of a cancer vaccine, its pathophysiological roles in glioma have not been investigated. Here, we analyzed the expression and function of DEPDC1 in malignant glioma. DEPDC1 expression in glioma cell lines, glioma tissues, and brain tumor initiating cells (BTICs) was assessed by western blot and quantitative polymerase chain reaction (PCR). The effect of DEPDC1 downregulation on cell growth and nuclear factor kappa B (NFκB) signaling in glioma cells was investigated. Overall survival was assessed in mouse glioma models using human glioma cells and induced mouse brain tumor stem cells (imBTSCs) to determine the effect of DEPDC1 suppression in vivo. DEPDC1 expression was increased in glioma cell lines, tissues, and BTICs. Suppression of endogenous DEPDC1 expression by small interfering RNA (siRNA) inhibited glioma cell viability and induced apoptosis through NFκB signaling. In mouse glioma models using human glioma cells and imBTSCs, downregulation of DEPDC1 expression prolonged overall survival. These results suggest that DEPDC1 represents a target molecule for the treatment of glioma. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 16 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 31% |
| Student > Bachelor | 3 | 19% |
| Student > Master | 2 | 13% |
| Student > Doctoral Student | 1 | 6% |
| Lecturer | 1 | 6% |
| Other | 0 | 0% |
| Unknown | 4 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 38% |
| Biochemistry, Genetics and Molecular Biology | 3 | 19% |
| Neuroscience | 1 | 6% |
| Engineering | 1 | 6% |
| Unknown | 5 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 June 2017.
All research outputs
#18,554,389
of 22,979,862 outputs
Outputs from Journal of Neuro-Oncology
#2,261
of 2,986 outputs
Outputs of similar age
#239,559
of 314,112 outputs
Outputs of similar age from Journal of Neuro-Oncology
#53
of 102 outputs
Altmetric has tracked 22,979,862 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,986 research outputs from this source. They receive a mean Attention Score of 4.2. This one is in the 13th percentile – i.e., 13% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 314,112 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 102 others from the same source and published within six weeks on either side of this one. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.